Cocrystal Pharma, Inc. (NasdaqCM: COCP)
Health Care · Pharmaceuticals · US
$1.06
-0.93% today · +0.9% 1Y
Cocrystal Pharma, Inc. (NasdaqCM: COCP) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $20.61M and employs 10 people.
Over the last twelve months the share price has gained 0.9%, trading between 0.76 and 2.03.
Tweenvest scores Cocrystal Pharma, Inc. across four factors: quality 46/100, value 77/100. Its strongest factor is value.
COCP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $20.61M
- Revenue (TTM)
- $330.00K
- P/E
- —
- EPS
- -0.76
- Dividend yield
- —
- Beta (5Y)
- 1.48
- 52-week high
- $2.03
- 52-week low
- $0.76
- Avg volume (3M)
- —
- Shares outstanding
- 19.26M
- Employees
- 10
- Next earnings
- —
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.
- ISIN
- US19188J4094
- Listed since
- Feb 22, 2012
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| MediPharm Labs Corp.TSX: LABS | $20.96M | CA$0.07 | 0.00% |
| Universe Pharmaceuticals INCNasdaqCM: UPC | $20.85M | $4.13 | -0.48% |
| Syschem (India) LimitedBSE: 531173 | $20.83M | Rs37.60 | +8.05% |
| Voyageur Pharmaceuticals Ltd.TSXV: VM | $20.62M | CA$0.13 | -7.14% |
| Scilex Holding CompanyNasdaqCM: SCLX | $20.54M | $2.86 | -2.23% |
| Biofrontera AGXTRA: B8FK | $20.34M | €2.99 | -18.75% |
| Nectar Lifesciences LimitedNSEI: NECLIFE | $20.33M | Rs10.13 | -0.98% |
| Bio Medica Laboratories LimitedNSEI: BMLL | $19.88M | Rs153.00 | -4.08% |
Figures last refreshed Oct 11, 2026.